New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
10:00 EDTDOV, HEK, PH, MGM, RDC, TKC, SPN, LUV, MKSI, MFC, LSTR, KKR, JOY, FTI, CELG, VTROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Celgene (CELG) upgraded to Outperform from Sector Perform at RBC Capital... Celgene (CELG) upgraded to Overweight from Neutral at Piper Jaffray... Dover (DOV) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Buy from Neutral at Sterne Agee... Joy Global (JOY) upgraded to Overweight from Neutral at Piper Jaffray... KKR & Co. (KKR) upgraded to Buy from Neutral at Goldman... Landstar System (LSTR) upgraded to Outperform from Market Perform at Wells Fargo... MKS Instruments (MKSI) upgraded to Buy from Neutral at BofA/Merrill... Manulife Financial (MFC) upgraded to Buy from Neutral at BofA/Merrill... Southwest (LUV) upgraded to Buy from Hold at Deutsche Bank... Superior Energy (SPN) upgraded to Outperform from Sector Perform at RBC Capital... Turkcell (TKC) upgraded to Overweight from Neutral at HSBC... Rowan Companies (RDC) upgraded to Neutral from Underweight at JPMorgan... MGM Resorts (MGM) upgraded to Outperform from Neutral at Credit Suisse... Parker-Hannifin (PH)upgraded to Overweight from Neutral at JPMorgan... Ventas (VTR) upgraded to Buy from Hold at Jefferies... Heckmann (HEK) upgraded to Neutral from Sell at Ladenburg.
News For DOV;CELG;FTI;JOY;KKR;LSTR;MFC;MKSI;LUV;SPN;TKC;RDC;MGM;PH;HEK;VTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 10, 2014
10:01 EDTVTROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:38 EDTMGMActive equity options trading on open
Subscribe for More Information
08:41 EDTCELGCelgene reports apremilast significantly improved preexisting psoriasis in study
Subscribe for More Information
08:39 EDTCELGCelgene says data show Apremilast treatment resulted in improved quality of life
Subscribe for More Information
06:16 EDTVTRVentas upgraded to Buy from Hold at Stifel
Stifel upgraded Ventas to Buy based on valuation. Price target is $70.
October 9, 2014
10:00 EDTMGMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Acuity Brands (AYI) upgraded at Oppenheimer... Agnico-Eagle (AEM) upgraded to Buy from Hold at Desjardins... Apple (AAPL) upgraded to Outperform from Perform at Oppenheimer... Bank of Montreal (BMO) upgraded to Buy from Hold at Canaccord... Basic Energy (BAS) upgraded to Hold from Underperform at Jefferies... BreitBurn Energy (BBEP) upgraded to Outperform from Perform at Oppenheimer... Golden Minerals (AUMN) upgraded at Roth Capital... Helmerich & Payne (HP) upgraded to Buy from Hold at Jefferies... II-VI (IIVI) upgraded to Buy from Neutral at DA Davidson... LivePerson (LPSN) upgraded at Credit Suisse... Luminex (LMNX) upgraded to Market Perform at Cowen... MGM Resorts (MGM) upgraded at Craig-Hallum... New Gold (NGD) upgraded to Buy from Hold at Desjardins... New Source Energy (NSLP) upgraded to Outperform from Perform at Oppenheimer... Pacific Coast Oil (ROYT) upgraded to Buy from Hold at Stifel... Pioneer Energy (PES) upgraded to Buy from Hold at Jefferies... Precision Drilling (PDS) upgraded to Strong Buy from Outperform at Raymond James... Randgold (GOLD) upgraded to Overweight from Neutral at HSBC... Resource Capital (RSO) upgraded to Buy from Hold at MLV & Co.... Toyota (TM) upgraded to Buy from Neutral at BofA/Merrill... Transocean (RIG) upgraded to Outperform from Sector Perform at Iberia... Universal Technical (UTI) upgraded to Outperform from Market Perform at Wells Fargo... Vulcan Materials (VMC) upgraded to Buy from Neutral at Longbow.
08:39 EDTMGMMGM Resorts upgraded at Craig-Hallum
Subscribe for More Information
08:03 EDTFTIFMC Technologies awarded frame agreement to supply subsea production systems
Subscribe for More Information
07:43 EDTMGMMGM Resorts upgraded to Buy from Hold at Craig-Hallum
Subscribe for More Information
October 8, 2014
08:46 EDTLUVSouthwest reports September RPMs up 5.1% to 8.3B
Southwest announced that the company flew 8.3 billion revenue passenger miles in September 2014, a 5.1% increase from the 7.9B RPMs flown in September 2013. Available seat miles increased 0.7% to 10.3B from the September 2013 level of 10.2B. The September 2014 load factor was 80.5%, compared to 77.1% in September 2013. For September, passenger revenue per ASM is estimated to have increased approximately 5% as compared to September 2013. For the third quarter of 2014, the Company flew 28.5B RPMs, compared to 27B RPMs flown for the same period in 2013, an increase of 5.6%. Third quarter 2014 ASMs increased 1.1% to 33.8B from third quarter 2013 ASMs of 33.4B . The third quarter 2014 load factor was 84.4%, compared to 80.8% for the same period in 2013.
07:11 EDTCELGEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
07:08 EDTKKRKKR coverage assumed with an Outperform at Credit Suisse
Subscribe for More Information
05:27 EDTMFCCanadian Solar announces $46M construction, term financing from Manulife
Subscribe for More Information
October 7, 2014
13:59 EDTKKRKKR invests in Lemonade Restaurant Group, terms not disclosed
Subscribe for More Information
10:08 EDTKKRSodaStream sinks after Q3 profit warning
Shares of SodaStream International (SODA) are sinking this morning after the company warned that revenue for the third quarter of 2014 will come in well below Wall Street estimates. SodaStream develops, manufactures and markets home beverage carbonation systems and related products. WHAT'S NEW: This morning, SodaStream reported preliminary Q3 revenue of $125M, significantly missing analysts' consensus estimate of about $154M. The company said it expects operating income of about $8.5M for the quarter. Chief Executive Officer Daniel Birnbaum cited an underperformance in the U.S. market as the primary driver of the quarterly shortfall, and said the results are an indication that the company must alter its course and improve its execution. Birnbaum said in a statement that the company is "very disappointed" by its recent performance, noting that it has "not succeeded in attracting new consumers to our home carbonation system at the rate we believe should be achieved." Birnbaum said the company has started a strategic shift towards health and wellness, mostly in the U.S., where he believes the message "will resonate more strongly" with customers. In addition, SodaStream is developing a growth plan, and more details are expected when Q3 results are reported later this month. WHAT'S NOTABLE: The carbonated beverage machine company has been the subject of buyout rumors for months. In July, Bloomberg reported that the company was in talks to go private for around $40 per share. In September, Israel's TheMarker said SodaStream was in talks to sell itself to a British investment fund for $840M, or $40 per share. SodaStream has also been rumored as an acquisition target for beverage makers SABMiller (SBMRY) and Diageo (DEO) or private equity group KKR (KKR), The Independent reported last month. In July, SodaStream cut its fiscal year 2014 revenue growth view to 5% from 15% and cut its FY14 net income expectations to a 5% decrease from a 3% increase. At that time, the company said it believed sales trends for sodamakers would remain challenging in the U.S. in the second half of the year. PRICE ACTION: In mid-morning trading, SodaStream shares dropped $5.72, or 21%, to $21.85.
10:02 EDTMGMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Air France-KLM (AFLYY) upgraded to Overweight from Underweight at JPMorgan... Alcobra (ADHD) upgraded to Outperform at FBR Capital... Alon USA Partners (ALDW) upgraded to Buy from Neutral at Citigroup... Becton Dickinson (BDX) upgraded to Buy from Hold at Stifel... CNOOC (CEO) upgraded at Bernstein... CTC Media (CTCM) upgraded to Buy from Hold at Deutsche Bank... CVR Refining (CVRR) upgraded to Buy from Neutral at Citigroup... CalAmp (CAMP) upgraded to Outperform from Neutral at Macquarie... China Unicom (CHU) upgraded to Overweight from Equal Weight at Barclays... Crown Holdings (CCK) upgraded at Macquarie... Dick's Sporting (DKS) upgraded to Buy from Neutral at Goldman... Fortuna Silver Mines (FSM) upgraded to Outperformer from Sector Performer at CIBC... Franco-Nevada (FNV) upgraded to Buy from Hold at TD Securities... Horsehead Holding (ZINC) upgraded to Outperform from Market Perform at FBR Capital... Ingersoll-Rand (IR) upgraded to Buy from Neutral at Goldman... IntercontinentalExchange (ICE) upgraded to Buy from Neutral at Citigroup... International Paper (IP) upgraded at BofA/Merrill... Leidos (LDOS) upgraded to Neutral from Underperform at Credit Suisse... Lennox (LII) upgraded to Positive from Neutral at Susquehanna... MGM Resorts (MGM) upgraded to Buy from Hold at Deutsche Bank... Natus Medical (BABY) upgraded to Outperform at William Blair... Noodles & Company (NDLS) upgraded to Buy from Hold at Jefferies... Phillips 66 (PSX) upgraded to Buy from Neutral at Citigroup... RockTenn (RKT) upgraded to Buy from Neutral at BofA/Merrill... Smith & Nephew (SNN) upgraded to Hold from Sell at Societe Generale... Sotheby's (BID) upgraded to Buy from Hold at Craig-Hallum... Sun Life Financial (SLF) upgraded to Overweight from Equal Weight at Barclays... WellCare (WCG) upgraded at Sterne Agee... Yamana Gold (AUY) upgraded to Neutral from Underweight at HSBC.
08:39 EDTMGMGaming stocks pullback creates attractive entry point, says Susquehanna
Subscribe for More Information
07:31 EDTCELGCelgene to present long-term efficacy and safety data on oral Otezla
Celgene International Sŕrl, a wholly-owned subsidiary of Celgene Corporation, announced that the latest research findings on OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4, in plaque psoriasis and psoriatic arthritis will be presented at the 23rd European Academy of Dermatology and Venereology Congress in Amsterdam, October 8 – 12. In total, 11 abstracts will be presented at the meeting. OTEZLA data to be presented include long-term results from Celgene’s pivotal trial, ESTEEM 2 and pooled analyses of safety and tolerability results from the ESTEEM 1 and 2 studies in patients with moderate to severe plaque psoriasis. Additional analyses will evaluate the effect of OTEZLA on pruritus, difficult-to-treat areas such as nail and scalp, and palmoplantar psoriasis, work productivity and improvements in health-related quality of life. An analysis of long-term results from the PALACE clinical trial program evaluating OTEZLA in patients with active psoriatic arthritis will also be presented at the meeting. The analysis assesses the effect of OTEZLA treatment through 52 weeks on the signs and symptoms of psoriatic arthritis, including enthesitis and dactylitis in patients with pre-existing enthesitis or dactylitis.
07:24 EDTCELGAlliance for Regenerative Medicine
Subscribe for More Information
05:55 EDTMGMMGM Resorts upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use